Tempus AI (NASDAQ:TEM) Shares Up 4% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s share price shot up 4% during trading on Wednesday . The company traded as high as $48.29 and last traded at $47.57. 3,538,763 shares traded hands during trading, a decline of 29% from the average session volume of 4,976,978 shares. The stock had previously closed at $45.74.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Stock Up 3.1 %

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a 50 day simple moving average of $55.65 and a two-hundred day simple moving average of $51.50.

Insider Activity at Tempus AI

In related news, Director Jennifer A. Doudna sold 1,320 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the completion of the transaction, the director now directly owns 36,011 shares of the company’s stock, valued at approximately $3,240,990. This represents a 3.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the transaction, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,561,814 shares of company stock valued at $315,485,164.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. bought a new position in Tempus AI during the third quarter valued at approximately $30,000. Operose Advisors LLC bought a new position in Tempus AI during the fourth quarter valued at approximately $25,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC raised its position in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC purchased a new stake in Tempus AI during the fourth quarter valued at approximately $49,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.